Poland
· Delayed Price · Currency is PLN Bioceltix Statistics
Total Valuation
Bioceltix has a market cap or net worth of PLN 342.25 million. The enterprise value is 322.42 million.
| Market Cap | 342.25M |
| Enterprise Value | 322.42M |
Important Dates
The last earnings date was Tuesday, September 24, 2024.
| Earnings Date | Sep 24, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioceltix has 4.92 million shares outstanding. The number of shares has increased by 16.64% in one year.
| Shares Outstanding | 4.92M |
| Shares Change (YoY) | +16.64% |
| Shares Change (QoQ) | +0.64% |
| Owned by Insiders (%) | 7.43% |
| Owned by Institutions (%) | 18.36% |
| Float | 3.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 7.62 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -20.51 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -23.29 |
Financial Position
The company has a current ratio of 7.21, with a Debt / Equity ratio of 0.47.
| Current Ratio | 7.21 |
| Quick Ratio | 3.26 |
| Debt / Equity | 0.47 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | -273.92 |
Financial Efficiency
Return on equity (ROE) is -50.19% and return on invested capital (ROIC) is -31.71%.
| Return on Equity (ROE) | -50.19% |
| Return on Assets (ROA) | -28.03% |
| Return on Capital (ROIC) | -31.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -561,390 |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.19% in the last 52 weeks. The beta is 1.87, so Bioceltix's price volatility has been higher than the market average.
| Beta (5Y) | 1.87 |
| 52-Week Price Change | +13.19% |
| 50-Day Moving Average | 72.17 |
| 200-Day Moving Average | 76.32 |
| Relative Strength Index (RSI) | 34.00 |
| Average Volume (20 Days) | 4,207 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.21M |
| Operating Income | -16.00M |
| Pretax Income | -15.74M |
| Net Income | -15.72M |
| EBITDA | -15.56M |
| EBIT | -16.00M |
| Earnings Per Share (EPS) | -3.80 |
Balance Sheet
The company has 20.04 million in cash and 210,029 in debt, giving a net cash position of 19.83 million or 4.03 per share.
| Cash & Cash Equivalents | 20.04M |
| Total Debt | 210,029 |
| Net Cash | 19.83M |
| Net Cash Per Share | 4.03 |
| Equity (Book Value) | 44.89M |
| Book Value Per Share | 9.12 |
| Working Capital | 43.33M |
Cash Flow
In the last 12 months, operating cash flow was -13.75 million and capital expenditures -99,062, giving a free cash flow of -13.85 million.
| Operating Cash Flow | -13.75M |
| Capital Expenditures | -99,062 |
| Free Cash Flow | -13.85M |
| FCF Per Share | -2.81 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bioceltix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.64% |
| Shareholder Yield | -16.64% |
| Earnings Yield | -5.47% |
| FCF Yield | -4.05% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |